Sesen Bio, Inc. is a late-stage clinical company engaged in advancing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company's advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).